Skip to main content

Table 2 Tacrolimus dosing pre- and 12 months post-conversion comparison by genotype: expressers (*1/*1 + *1/*3) and non-expressers (*3/*3)

From: The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients

Variable

*1/*1 and *1/*3

*3/*3

p value

N = 17

N = 43

Required Tac dose increase (%)

10 (59)

20 (47)

0.004

Tac BID (mg/day)

4.6 ± 2.7

2.4 ± 1.2

0.0003

Tac OD (mg/day)

6 ± 2.7

2.9 ± 1.2

0.0001

Tac dose adjustment from BID to OD (%)

45.3 ± 48.3

26.6 ± 32.1

0.003

  1. BID twice daily, OD once daily, Tac tacrolimus
  2. *1/*3 expressers; *3/*3 non-expressers